Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis
Study limitation reported by the research below: “Placebo group showed an unexpectedly rapid eGFR decline (-5.69 mL/min/1.73 m² at 52 weeks), which may reflect a higher-risk population and limit generalizability to all IgA nephropathy patients.”